GET DAILY SIGNALSZura Bio (ZURA): Can the Stock Close the Gap to the $18 Analyst Target?
Key Takeaways
- The central target of $18 is the arithmetic mean of seven verified analyst price targets, which span a wide range from $11 to $26.
- Before a pivotal November 2026 trial announcement, shares of Zura Bio traded near $4.09, implying a required move of roughly 340% to reach $18 — a very large gap.
- Zura Bio's lead candidate tibulizumab failed its Phase 2 hidradenitis suppurativa (HS) trial, missing its primary and key secondary endpoints and triggering a steep pre-market sell-off.
- The strongest supporting factor is a diversified immunology pipeline — including crebankitug (ZB-168) in alopecia areata and torudokimab in inflammatory disease — plus a cash position of roughly $188 million.
- The biggest risk is that the HS failure undermines confidence in the lead program and is likely to prompt downward analyst target revisions.
- For deeper context, explore Major News, Today's Price Move, Forecast, and Earnings pages for ZURA.
- To scan for AI-generated trading ideas across the market, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Zura Bio Limited (ZURA) is a clinical-stage, multi-asset immunology biotechnology company. A review of seven recent, attributed analyst price targets produced a mean of roughly $17.71, rounded to a central target of $18. The individual figures are Wedbush ($22, October 2026), Piper Sandler ($26, October 2026), Guggenheim ($20, October 2026), Leerink Partners ($11, October 2026), Oppenheimer ($16, June 2026), Chardan Capital ($11, May 2026) and Clear Street ($18, December 2025), giving a low-to-high range of $11 to $26.
The wide range reflects genuinely different views on clinical-stage risk. Higher targets from Piper Sandler, Wedbush and Guggenheim emphasize the breadth of Zura Bio's pipeline and multiple upcoming data catalysts, while the lower Leerink and Chardan figures apply more conservative risk adjustments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Crucially, all seven targets were issued before Zura Bio disclosed that tibulizumab missed its primary endpoint in a Phase 2 hidradenitis suppurativa study, so they may be revised sharply lower. The $18 figure is a calculated mean of these targets, not an official published consensus.
Current Market Position and Path Toward the Target
Shares closed near $4.09 before the November 2026 trial disclosure and then fell roughly 68% in pre-market trading to about $1.30, according to Reuters, after tibulizumab failed to beat placebo on lesion-reduction endpoints. Even measured from the pre-announcement close of about $4.09, reaching $18 requires an upside of approximately 340% — a very large move. The company plans to discontinue tibulizumab development in hidradenitis suppurativa while continuing studies in systemic sclerosis (TibuSURE, data expected in the first half of 2027) and other inflammatory indications. A path back toward higher levels would likely require the systemic sclerosis program, crebankitug (ZB-168) in alopecia areata, or torudokimab to deliver positive data and restore investor confidence.
What Could Support a Move Toward the Target
- Diversified pipeline: crebankitug (ZB-168), an anti-IL-7Rα antibody for alopecia areata, and torudokimab (ZB-880), an anti-IL-33 antibody, remain independent shots on goal.
- Ongoing tibulizumab programs: the systemic sclerosis (TibuSURE) study completed enrollment with 91 participants and is expected to read out in the first half of 2027.
- Balance sheet: total cash of roughly $188 million provides runway to fund clinical development.
- Analyst positioning: before the HS setback, every recent rating was a Buy, reflecting optimism about the broader platform.
What Could Prevent the Target From Being Reached
- Tibulizumab HS failure: the lead program missed its primary and key secondary endpoints, forcing the company to halt development in that indication and calling the bispecific's broader promise into question.
- Downward revisions: analyst price targets built partly on tibulizumab are likely to be cut, and the $18 mean may no longer reflect current expectations.
- Clinical and execution risk: as a pre-revenue biotech, Zura Bio depends entirely on trial outcomes, and setbacks can erase large amounts of value quickly.
- Elevated short interest: roughly 18.6% of the float was sold short before the decline, reflecting persistent skepticism.
Technical Levels and Market Structure
Before the trial news, the stock was already trading near the bottom of its 52-week range of $3.25 to $7.44 and below its 200-day moving average. The pre-market decline broke through that prior $3.25 floor, leaving earlier support levels far overhead. In a post-failure environment, psychological round numbers and any stabilization zone that forms after the gap down are more relevant references than the old range. The wide bid-ask spread and micro-cap status can amplify volatility in either direction.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts may use different assumptions, and the pending revisions make the current horizon uncertain. Investors should monitor whether analysts lower their targets in response to the HS failure, the systemic sclerosis (TibuSURE) readout expected in the first half of 2027, crebankitug and torudokimab development updates, cash burn and runway disclosures, and quarterly results. Regulatory decisions and the broader appetite for speculative biotechnology names will also matter.
Using AI Tools for Market Monitoring
In my own process, I often reference Tickeron’s AI Daily Buy/Sell Signals when following names with upcoming clinical catalysts. The system applies artificial intelligence to scan thousands of stocks and generate signals based on technical behavior and market conditions. For a volatile name like Zura Bio, it can help identify shifting trends more efficiently than manual review alone.
Final Assessment
The $18 target is the average of seven pre-setback analyst price targets ranging from $11 to $26. After tibulizumab's Phase 2 hidradenitis suppurativa failure and the subsequent price collapse toward $1.30, the distance to $18 has widened dramatically, and the target itself is likely to be revised lower as analysts absorb the news. The strongest remaining supports are the diversified pipeline, the systemic sclerosis readout ahead, and a sizable cash balance, while the principal obstacles are the lead-program failure, probable target cuts, and high short interest. Reaching $18 would require a multi-year, multi-program turnaround rather than a single positive catalyst. Investors should focus on upcoming data readouts and analyst revisions rather than treating the $18 figure as a reliable forecast.
Exploring Tickeron AI Tools
From what I see in my research, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to monitor technical shifts and generate trading ideas across a broad universe of stocks. The platform continuously analyzes market data to produce Buy, Sell, or Hold signals, which can be especially useful when tracking catalyst-driven names and adjusting positions as conditions evolve. Traders can explore the signals to discover opportunities and respond more quickly to changes in technical setups.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ZURA's RSI Oscillator is remaining in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZURA advanced for three days, in 153 of 188 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ZURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZURA as a result. In 51 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for ZURA turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 40 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ZURA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.989) is normal, around the industry mean (3.498). P/E Ratio (-3.652) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ZURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology